St. Jude Children’s Research Hospital scientists improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab. (IMAGE)

St. Jude Children's Research Hospital

St. Jude Children’s Research Hospital scientists improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab.

Caption

(L to R) First author Jaquelyn Zoine, PhD, senior corresponding author Paulina Velasquez, MD, St. Jude Department of Bone Marrow Transplantation and Cellular Therapy, co-author M. Madan Babu, PhD, FRS, St. Jude Department of Structural Biology and second author Kalyan Immadisetty, St. Jude Department of Bone Marrow Transplantation and Cellular Therapy.

Credit

Courtesy of St. Jude Children's Research Hospital

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.